Early Increase of Cerebrospinal Fluid 14-3-3ζ Protein in the Alzheimer's Disease Continuum

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2022 Aug 15

PMID 35966774

Authors

Yuanyuan Lu

Affiliations

Soon will be listed here.

Abstract

Background: The earlier research has shown that the 14-3-3ζ is increased in neurofibrillary tangles (NFTs) of human Alzheimer's disease (AD) brains and stimulates the tau phosphorylation. Cerebrospinal fluid (CSF) 14-3-3ζ along the AD continuum remains to be explored.

Methods: We analyzed 113 cognitive normal (CN) controls, 372 patients with mild cognitive impairment (MCI), and 225 patients with AD dementia from the Alzheimer's Disease Neuroimaging Initiative database. CSF 14-3-3ζ protein was measured by Mass Spectrometry.

Results: We observed higher CSF 14-3-3ζ in the MCI group vs. the CN group and in the AD group vs. the MCI or CN group. The 14-3-3ζ was able to distinguish AD from CN and MCI. High 14-3-3ζ predicted conversion from MCI to AD. In CSF, phosphorylated tau at threonine 181 and total-tau were associated with 14-3-3ζ in MCI and AD groups, and beta-amyloid (Aβ) 42 correlated with 14-3-3ζ in the MCI group. Baseline high 14-3-3ζ was associated with cognitive decline, brain atrophy, glucose hypometabolism, and Aβ deposition in MCI and AD at baseline and follow-up.

Conclusion: Our findings revealed the potential diagnostic and prognostic utility of CSF 14-3-3ζ in the AD continuum. The 14-3-3ζ could be a promising therapeutic target for the intervention of AD.

Citing Articles

Biological mechanisms of resilience to tau pathology in Alzheimer's disease.

Svenningsson A, Bocancea D, Stomrud E, van Loenhoud A, Barkhof F, Mattsson-Carlgren N Alzheimers Res Ther. 2024; 16(1):221.

PMID: 39396028 PMC: 11470552. DOI: 10.1186/s13195-024-01591-9.

Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer's disease.

Eteleeb A, Novotny B, Tarraga C, Sohn C, Dhungel E, Brase L PLoS Biol. 2024; 22(4):e3002607.

PMID: 38687811 PMC: 11086901. DOI: 10.1371/journal.pbio.3002607.

14-3-3 proteins-a moonlight protein complex with therapeutic potential in neurological disorder: in-depth review with Alzheimer's disease.

Abdi G, Jain M, Patil N, Upadhyay B, Vyas N, Dwivedi M Front Mol Biosci. 2024; 11:1286536.

PMID: 38375509 PMC: 10876095. DOI: 10.3389/fmolb.2024.1286536.

Formation of amyloid fibrils by the regulatory 14-3-3 protein.

Sulskis D, Ziaunys M, Sakalauskas A, Snieckute R, Smirnovas V Open Biol. 2024; 14(1):230285.

PMID: 38228169 PMC: 10791532. DOI: 10.1098/rsob.230285.

14-3-3 -reported early synaptic injury in Alzheimer's disease is independently mediated by sTREM2.

Woo M, Nilsson J, Therriault J, Rahmouni N, Brinkmalm A, Benedet A J Neuroinflammation. 2023; 20(1):278.

PMID: 38001539 PMC: 10675887. DOI: 10.1186/s12974-023-02962-z.

References

Blennow K, Shaw L, Stomrud E, Mattsson N, Toledo J, Buck K . Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays. Sci Rep. 2019; 9(1):19024. PMC: 6911086. DOI: 10.1038/s41598-019-54204-z. View

Nilsson J, Gobom J, Sjodin S, Brinkmalm G, Ashton N, Svensson J . Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease. Alzheimers Dement (Amst). 2021; 13(1):e12179. PMC: 8087978. DOI: 10.1002/dad2.12179. View

Fu H, Subramanian R, Masters S . 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol. 2000; 40:617-47. DOI: 10.1146/annurev.pharmtox.40.1.617. View

Cornell B, Toyo-Oka K . 14-3-3 Proteins in Brain Development: Neurogenesis, Neuronal Migration and Neuromorphogenesis. Front Mol Neurosci. 2017; 10:318. PMC: 5643407. DOI: 10.3389/fnmol.2017.00318. View

Llorens F, Schmitz M, Karch A, Cramm M, Lange P, Gherib K . Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia. Alzheimers Dement. 2016; 12(5):577-89. DOI: 10.1016/j.jalz.2015.10.009. View

Umahara T, Uchihara T, Tsuchiya K, Nakamura A, Iwamoto T, Ikeda K . 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer's disease. Acta Neuropathol. 2004; 108(4):279-86. DOI: 10.1007/s00401-004-0885-4. View

Jack Jr C, Wiste H, Weigand S, Knopman D, Mielke M, Vemuri P . Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain. 2015; 138(Pt 12):3747-59. PMC: 4655341. DOI: 10.1093/brain/awv283. View

Qureshi H, Han D, MacDonald R, Paudel H . Overexpression of 14-3-3z promotes tau phosphorylation at Ser262 and accelerates proteosomal degradation of synaptophysin in rat primary hippocampal neurons. PLoS One. 2013; 8(12):e84615. PMC: 3868614. DOI: 10.1371/journal.pone.0084615. View

Foote M, Zhou Y . 14-3-3 proteins in neurological disorders. Int J Biochem Mol Biol. 2012; 3(2):152-64. PMC: 3388734. View

10.

Chen Y, Chen X, Yao Z, Shi Y, Xiong J, Zhou J . 14-3-3/Tau Interaction and Tau Amyloidogenesis. J Mol Neurosci. 2019; 68(4):620-630. DOI: 10.1007/s12031-019-01325-9. View

11.

Nelson T, Alkon D . Protection against beta-amyloid-induced apoptosis by peptides interacting with beta-amyloid. J Biol Chem. 2007; 282(43):31238-49. DOI: 10.1074/jbc.M705558200. View

12.

He Y, Han J, Chang O, Oh M, James S, Lu Q . 14-3-3ɛ/ζ Affects the stability of δ-catenin and regulates δ-catenin-induced dendrogenesis. FEBS Open Bio. 2013; 3:16-21. PMC: 3668525. DOI: 10.1016/j.fob.2012.11.006. View

13.

Sadik G, Tanaka T, Kato K, Yanagi K, Kudo T, Takeda M . Differential interaction and aggregation of 3-repeat and 4-repeat tau isoforms with 14-3-3zeta protein. Biochem Biophys Res Commun. 2009; 383(1):37-41. DOI: 10.1016/j.bbrc.2009.03.107. View

14.

Park S, Jung J, Park J, Lee J, Park B, Kim H . SWATH-MS analysis of cerebrospinal fluid to generate a robust battery of biomarkers for Alzheimer's disease. Sci Rep. 2020; 10(1):7423. PMC: 7198522. DOI: 10.1038/s41598-020-64461-y. View

15.

Aisen P, Petersen R, Donohue M, Gamst A, Raman R, Thomas R . Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement. 2010; 6(3):239-46. PMC: 2867843. DOI: 10.1016/j.jalz.2010.03.006. View

16.

Layfield R, Fergusson J, Aitken A, Lowe J, Landon M, Mayer R . Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Neurosci Lett. 1996; 209(1):57-60. DOI: 10.1016/0304-3940(96)12598-2. View

17.

Aitken A, Howell S, Jones D, Madrazo J, Patel Y . 14-3-3 alpha and delta are the phosphorylated forms of raf-activating 14-3-3 beta and zeta. In vivo stoichiometric phosphorylation in brain at a Ser-Pro-Glu-Lys MOTIF. J Biol Chem. 1995; 270(11):5706-9. DOI: 10.1074/jbc.270.11.5706. View

18.

Hampel H, Burger K, Teipel S, Bokde A, Zetterberg H, Blennow K . Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008; 4(1):38-48. DOI: 10.1016/j.jalz.2007.08.006. View

19.

Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski J, Bittner T . CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018; 14(11):1470-1481. PMC: 6119541. DOI: 10.1016/j.jalz.2018.01.010. View

20.

Mateo I, Llorca J, Infante J, Rodriguez-Rodriguez E, Berciano J, Combarros O . Gene-gene interaction between 14-3-3 zeta and butyrylcholinesterase modulates Alzheimer's disease risk. Eur J Neurol. 2008; 15(3):219-22. DOI: 10.1111/j.1468-1331.2008.02059.x. View